Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Nausea and vomiting].

Masato Fujii1

  • 1Department of Otolaryngology, School of Medicine, Keio University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 17, 2003
PubMed
Summary
This summary is machine-generated.

Chemotherapy-induced nausea and vomiting (CINV) are distressing side effects. While 5-HT3 receptor antagonists effectively manage acute emesis, delayed emesis control remains limited, necessitating further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer.

Scientific reports·2026
Same author

Staple-line-associated lung adenocarcinoma years after video-assisted thoracoscopic surgical bullectomy for pneumothorax.

Respiratory medicine case reports·2026
Same author

Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD.

Scientific reports·2026
Same author

Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.

Japanese journal of clinical oncology·2026
Same author

Biological Aging and Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Receiving Systemic Therapy.

Clinical lung cancer·2025
Same author

Long-acting muscarinic antagonist versus leukotriene receptor antagonist as additional treatment in uncontrolled asthma patients used inhaled corticosteroids and long-acting β2 adrenergic agonist: a randomized phase 2 screening trial.

Respiratory medicine and research·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Context:

  • Chemotherapy-induced nausea and vomiting (CINV) are significant adverse effects of cancer treatment, particularly with cisplatin-based chemotherapy (CDDP).
  • Current anti-emetic strategies include dopamine receptor antagonists, corticosteroids, and serotonin 5-HT3 receptor antagonists.

Purpose:

  • To review the efficacy of anti-emetic agents, focusing on 5-HT3 receptor antagonists for managing chemotherapy-induced nausea and vomiting.
  • To highlight the effectiveness of 5-HT3 receptor antagonists in acute versus delayed emesis and the role of psychiatric medications.

Summary:

  • 5-HT3 receptor antagonists like Granisetron, Ondansetron, Ramosetron, and Azasetron demonstrate high efficacy (80%) in controlling acute chemotherapy-induced vomiting.
  • However, their effectiveness for delayed emesis is considerably lower (20%).

Related Experiment Videos

  • Psychiatric medications are valuable for managing persistent or conditioned nausea and vomiting.

    • Impact:

    • Improved management strategies for CINV can significantly enhance patient quality of life during cancer therapy.
    • Understanding the differential efficacy of anti-emetics for acute and delayed emesis guides clinical practice and patient care.
    • Further research into managing delayed emesis and anticipatory nausea is warranted.